MGMaksymilian Głaz

Maksymilian Głaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maksymilian Głaz has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    LITHIUM AND ALZHEIMER’S DISEASE: POTENTIAL NEUROPROTECTIVE EFFECTS AND THERAPEUTIC PERSPECTIVES

    by Dominika Matecka, Weronika Pura, Jakub Mazur, Mateusz Kosowski, Jakub Marciniak, Daniel Chołuj, Karolina Zarówna, Beata Huszcza, Maksymilain Głaz

    Lithium is an established mood stabilizer whose possible use in Alzheimer’s disease (AD) has emerged from convergent molecular, animal, observational, and early clinical evidence. The principal rationale is that lithium may act on several processes implicated in AD rather than on a single lesion: glycogen synthase kinase-3β (GSK-3β) signaling, tau phosphorylation, amyloid precursor protein processing, neuroinflammation, oxidative and mitochondrial stress, autophagy, neurogenesis, and synaptic plasticity. Animal studies generally report preserved memory and reduced amyloid-related pathology, while small human studies suggest that subtherapeutic lithium may attenuate cognitive decline or modify cerebrospinal-fluid biomarkers. Observational cohorts also associate lithium exposure with lower dementia incidence, but these findings are vulnerable to confounding by indication, comorbidity, treatment adherence, and healthcare use. Evidence is not uniformly positive: a Scottish cohort exposed to extremely low environmental lithium did not support dementia protection, and a recent randomized feasibility trial in mild cognitive impairment found no significant effect on any of six prespecified coprimary outcomes, although one memory measure declined more slowly with lithium. The therapeutic challenge is therefore not simply whether lithium is neuroprotective, but which patients, dose, formulation, exposure duration, and biomarker-defined disease stage are most likely to benefit. Lithium remains an investigational strategy for AD prevention or treatment, not a substitute for established clinical care.

  • Open Access

    PERORAL PANCREATOSCOPY IN THE EVALUATION AND MANAGEMENT OF PANCREATIC DUCT DISORDERS: A NARRATIVE REVIEW

    by Wojciech Sołtys, Magdalena Stolarczyk, Aleksandra Jagura-Sukiennik, Cezary Kosmecki, Mateusz Stronczyński, Łukasz Deska, JęDrzej Zaguła, Justyna Jankowska, Natalia Kamińska, Dawid Głaz, et al.

    Background: Peroral pancreatoscopy is an advanced endoscopic modality that enables direct visualization of the pancreatic duct. It may be useful when cross-sectional imaging, endoscopic ultrasound, or conventional endoscopic retrograde cholangiopancreatography do not provide sufficient information on intraductal pancreatic pathology. Aim: This review aimed to summarize the current diagnostic and therapeutic applications of peroral pancreatoscopy, with emphasis on intraductal papillary mucinous neoplasms, indeterminate pancreatic duct strictures or dilatation, and pancreatic duct stone disease. Material and methods: This narrative review was based on available literature concerning the clinical utility of peroral pancreatoscopy in pancreatic duct disorders. Particular attention was given to studies evaluating intraductal lesion morphology, preoperative and intraoperative mapping, diagnostic assessment of indeterminate ductal abnormalities, and pancreatoscopy-guided lithotripsy. Results: Current evidence suggests that pancreatoscopy may provide additional clinically relevant information in selected patients with intraductal papillary mucinous neoplasms by improving assessment of ductal morphology and disease extent. In indeterminate pancreatic duct strictures or unexplained ductal dilatation, it may support diagnostic evaluation through direct visualization and targeted tissue acquisition. Therapeutically, pancreatoscopy-guided lithotripsy has shown favorable efficacy in difficult pancreatic duct stones. However, broader use is limited by technical complexity, operator dependence, restricted availability, and adverse events, particularly post-procedural pancreatitis. Conclusions: Peroral pancreatoscopy is a valuable complementary tool in selected cases of pancreatic duct disease. Further prospective studies, procedural standardization, and consistent safety reporting are needed to define its role in routine practice.

  • Open Access

    TIME-CRITICAL SURGICAL ACUTE ABDOMEN: A NARRATIVE REVIEW OF DIAGNOSTIC PATHWAYS, ESCALATION PROCESSES, AND MULTIDISCIPLINARY CARE

    by JęDrzej Zaguła, Cezary Kosmecki, Mateusz Stronczynski, Łukasz Deska, Dawid Głaz, Maksymilan Głaz, Natalia Kamińska, Aleksandra Jagura-Sukiennik, Magdalena Stolarczyk, Wojciech Sołtys

    Introduction: Acute abdominal pathology remains a common and diagnostically challenging emergency presentation. A clinically important subset requires urgent surgical or interventional management, and delays may lead to bowel necrosis, sepsis, shock, multi-organ failure, and death. Methods: A structured search of PubMed/MEDLINE, PubMed Central, Scopus, and Google Scholar was performed. International guidelines, systematic reviews, meta-analyses, and clinically relevant observational studies were prioritised, with a focus on obstruction, ischaemia, perforation, intra-abdominal infection, biliary emergencies, haemorrhage, and trauma-related abdominal pathology. Results: The reviewed evidence shows that the surgical acute abdomen is mainly driven by obstruction, ischaemia, perforation/infection, and haemorrhage. Early diagnosis remains difficult because symptoms may be non-specific and presentations atypical, especially in older or comorbid patients. Repeated reassessment, risk-based imaging, early recognition of red-flag features, and timely surgical consultation are consistently associated with improved outcomes. Conclusions: Effective management of the acute abdomen requiring surgical intervention depends on early recognition of time-critical pathology, structured diagnostic pathways, and prompt source control. Further research should focus on standardised care pathways that reduce time-to-intervention while maintaining patient safety.

  • Open Access

    MODERN TECHNOLOGICAL SOLUTIONS IN THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA: A REVIEW OF INNOVATIONS AND THEIR SOCIAL IMPACT

    by Mateusz Stronczyński, Dawid Głaz, Szymon Zysiak, Maksymilian Głaz, Natalia Kamińska, JęDrzej Zaguła, Magdalena Stolarczyk, Wojciech Sołtys, Aleksandra Jagura-Sukiennik, Łukasz Deska

    Introduction: The aim of this review is to analyze technological advancements in the treatment of Obstructive Sleep Apnea (OSA) published between 2019 and 2025, with a specific focus on their impact on therapeutic adherence and public health. Materials and methods: A comprehensive literature review was conducted utilizing key databases such as PubMed, Scopus, Web of Science, and Google Scholar. The selection process prioritized innovative technological solutions, telemedicine applications, and e-health concepts. Results: The comprehensive review of the scientific literature revealed several technological advancements significantly impacting the treatment of Obstructive Sleep Apnea: Hypoglossal Nerve Stimulation: HNS serves as an effective alternative for moderate to severe OSA patients intolerant to CPAP [1]. This implantable treatment stimulates the hypoglossal nerve, activating muscles to maintain upper airway patency during sleep, resulting in significant reductions in Apnea-Hypopnea Index and improved sleep quality [2,3]. Advanced Algorithms in PAP Devices: Integrating AI and machine learning into PAP devices optimizes treatment and boosts patient adherence [4]. These algorithms analyze CPAP data to predict adherence issues, enabling clinicians to tailor interventions and personalize strategies for better patient outcomes [5]. Telemedicine: Telemedicine has advanced OSA management through remote patient interaction, monitoring, and follow-up [6]. This remote care often leads to comparable or improved treatment compliance, offering cost-effective solutions and increasing access to specialized care [7]. 3D Printing in Oral Appliances: 3D printing revolutionizes the fabrication of custom Mandibular Advancement Devices for OSA [8,9]. Utilizing digital workflows from intraoral scanning to CAD design, highly precise appliances are produced, improving patient comfort and adherence [9]. Conclusion: The introduction of new technologies in OSA treatment, such as hypoglossal nerve stimulation, improved algorithms in PAP devices, telemedicine, and 3D printing, holds significant potential for increasing patient therapeutic adherence [10]. These technologies favor therapy personalization, which is crucial given the diverse pathophysiology and phenotypes of OSA [2]. Improved compliance and the availability of personalized treatment methods directly translate into better public health outcomes, a reduction in the risk of cardiovascular and metabolic complications, and an overall improvement in the quality of life for OSA patients [11, 12]. However, attention must be paid to ensuring that the implementation of these innovations is conducted thoughtfully, so as not to exacerbate existing inequalities in access to healthcare [12].

  • Open Access

    MOBILE HEALTH APPLICATIONS IN MANAGEMENT OF POLYCYSTIC OVARY SYNDROME (PCOS): A SYSTEMATIC REVIEW OF CLINICAL EFFICACY, QUALITY, AND SOCIO-ECONOMIC IMPLICATIONS

    by Maksymilian Głaz, Łukasz Deska, Szymon Zysiak, Dawid Głaz, Natalia Kamińska, Jędrzej Zaguła, Wojciech Sołtys, Cezary Kosmecki, Mateusz Stronczyński, Kacper Wicha

    Background: Polycystic Ovary Syndrome (PCOS) constitutes the most prevalent endocrine disorder in reproductive-aged women, affecting approximately 8–13% of this population globally. Although lifestyle modification is the designated first-line therapy, adherence is frequently impeded by economic barriers and the lack of continuous, personalized support. Mobile health (mHealth) technologies propose a scalable solution to this "care gap," yet the digital marketplace remains fragmented, often lacking alignment between commercial usability and clinical evidence. Objectives: This systematic review evaluates the clinical efficacy, technical quality, and socio-economic implications of mHealth interventions in PCOS management to inform future clinical practice and reimbursement frameworks. Methods: A systematic search of academic databases covering the period from January 2010 to January 2025 yielded 34 eligible studies. These included Randomized Controlled Trials (RCTs) assessing clinical outcomes and content analyses utilizing the Mobile App Rating Scale (MARS). Results: Evidence from high-quality RCTs indicates that integrated mHealth interventions can function as effective "digital scaffolds" for behavioral change. Specific digital interventions demonstrated significant weight reduction (mean -3.19 kg) and improved insulin resistance with efficacy comparable to metformin. Furthermore, digital support significantly restored reproductive function, with long-term data showing a substantial increase in the prevalence of regular menstrual cycles, rising from 3.3% at baseline to 43.1% in intervention groups. However, technical analyses reveal a persistent "quality gap," where commercial applications prioritize aesthetics over evidence-based medical content. Conclusion: Mobile health applications represent a clinically valid and cost-effective adjunct to standard PCOS care. To realize their public health potential, future frameworks must bridge the divide between commercial user experience and academic rigor, ensuring equitable access to validated digital therapeutics.

  • Open Access

    PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

    by Łukasz Deska, Cezary Kosmecki, Dawid Głaz, Natalia Kamińska, Wojciech Sołtys, Magdalena Stolarczyk, Maksymilian Głaz, Mateusz Stronczyński, Aleksandra Jagura-Sukiennik, Julia Wawerska

    This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing from systematic reviews, meta-analyses, and clinical trials identified through targeted database searches. Key findings indicate that psilocybin therapy demonstrates rapid, robust, and sustained antidepressant effects, with high response and remission rates, often after one or two sessions. Its safety profile is generally favorable, with transient and mild adverse events. Mechanistically, psilocybin primarily acts on serotonin 5-HT2A receptors, modulating brain networks and enhancing neuroplasticity. However, significant challenges exist in terms of high costs, limited accessibility due to the intensive therapeutic model, and regulatory hurdles. In conclusion, psilocybin-assisted therapy offers a promising alternative for depression, particularly where standard treatments fail, by providing rapid and durable symptom reduction through unique neurobiological pathways. Future research should focus on optimizing treatment protocols, exploring long-term outcomes, identifying predictors of response, and addressing systemic barriers to accessibility and cost-effectiveness to facilitate its integration into broader mental healthcare.

  • Open Access

    COGNITIVE IMPAIRMENT, FATIGUE, AND WORKPLACE ACCOMMODATIONS IN MULTIPLE SCLEROSIS: IMPACT ON EMPLOYMENT RETENTION

    by Cezary Kosmecki, Szymon Zysiak, Dawid Głaz, Łukasz Deska, Magdalena Stolarczyk, Wojciech Sołtys, Natalia Kamińska, Maksymilian Głaz, Jędrzej Zaguła, Aleksandra Jagura-Sukiennik

    Multiple Sclerosis significantly impacts employment retention due to its early onset and progressive nature, necessitating a comprehensive understanding of contributing factors beyond physical disability. This narrative review explores the profound influence of cognitive impairment, fatigue, and the efficacy of workplace accommodations on maintaining employment for individuals with MS. Specifically, this review synthesizes current literature to delineate how these non-physical symptoms frequently precipitate job loss and absenteeism among people with MS (pwMS). Beyond merely physical limitations, factors such as fatigue, cognitive decline, and mental health issues are significant predictors of reduced working hours and early retirement for individuals with MS (Pokryszko-Dragan et al., 2022). These non-motor symptoms can create a complex "vicious circle" that adversely affects vocational status, often intertwining with mental health challenges that independently influence professional activities (Pokryszko‐Dragan et al., 2022). The diverse manifestations of MS, encompassing motor, sensory, and cognitive deficits, along with chronic fatigue, significantly impede work performance and overall quality of life (Pokryszko-Dragan et al., 2022; Valadkevičienė et al., 2024). While previous research has identified disease severity, fatigue, and cognitive impairments as key predictors of employment outcomes, persistent limitations in generalizability stem from sample variability, socioeconomic factors, and diverse healthcare systems (Iron et al., 2025). This narrative review aims to comprehensively address these gaps by synthesizing evidence on the multifaceted interplay between cognitive impairment, fatigue, workplace accommodations, and their collective impact on employment retention in MS. Understanding these intricate relationships is critical for developing targeted interventions and supportive strategies to enhance vocational longevity for individuals living with MS (Moccia et al., 2022; Pokryszko‐Dragan et al., 2022).

  • Open Access

    THE QUANTIFIED RUNNER’S KNEE: A SOCIO-TECHNICAL REVIEW OF ILIOTIBIAL BAND DYNAMICS, DIGITAL DIAGNOSTICS, AND REGENERATIVE INNOVATION

    by Dawid Głaz, Łukasz Deska, Szymon Zysiak, Maksymilian Głaz, Natalia Kamińska, Jędrzej Zaguła, Wojciech Sołtys, Cezary Kosmecki, Mateusz Stronczyński, Kacper Wicha

    The global proliferation of recreational running has evolved from a simple health behavior into a complex socio-technical phenomenon, deeply embedded in the digital economy. While the "running boom" has yielded cardiovascular benefits, it has precipitated an epidemic of musculoskeletal injuries, notably Iliotibial Band Syndrome (ITBS) and Patellofemoral Pain (PFP). Traditionally viewed through a reductionist biomedical lens, the etiology of these injuries is increasingly mediated by technological factors—from "quantified self" metrics driving training loads to Artificial Intelligence (AI) in diagnostics. This review synthesizes biomechanical evidence linking iliotibial band tension to Chondromalacia Patellae (CMP) via Lateral Patellar Compression Syndrome (LPCS) and integrates this into a sociological framework. We examine how wearable technology creates a "paradox of data" that may exacerbate overuse injuries. Furthermore, we evaluate the economic burden on healthcare systems and workforce productivity. Finally, we propose an integrated therapeutic model combining biomechanical correction with regenerative medicine (mesenchymal stem cells) and digital health interventions. This interdisciplinary review argues that effective injury management requires a convergence of orthopedic precision and sociological insight.

  • Open Access

    MEDULLARY THYROID CARCINOMA (MTC): A CURRENT REVIEW OF EPIDEMIOLOGY, DIAGNOSIS, AND THERAPY

    by Szymon Zysiak, Julia Wawerska, Dawid Głaz, Maksymilian Głaz, Natalia Kamińska, JęDrzej Zaguła, Magdalena Stolarczyk, Aleksandra Jagura-Sukiennik, Mateusz Stronczyński, Kacper Wicha

    Background: Medullary Thyroid Carcinoma (MTC) is a rare neuroendocrine tumor (1–5% of all thyroid cancers) characterized by disproportionately high mortality (13%), often complicated by advanced-stage diagnosis and early metastasis. This malignancy is uniquely driven by RET proto-oncogene mutations. Aim: This review aims to comprehensively analyze contemporary MTC management strategies, focusing on advancements in precision diagnostics, targeted therapies, and identifying critical challenges related to therapeutic resistance and clinical guideline standardization. Materials and Methods: An extensive synthesis of the current literature, prioritizing comprehensive review articles and meta-analyses published within the last five years, was conducted using multiple electronic databases (PubMed, Scopus). Results: Recent breakthroughs include the highly effective and well-tolerated selective RET inhibitors (selpercatinib, pralsetinib), which offer improved outcomes compared to older multikinase inhibitors (MKIs). Diagnostic modalities are enhanced by advanced functional imaging (e.g. [18F]F-DOPA-PET/CT). Despite improved overall survival, the major clinical hurdle remains acquired drug resistance, mediated by RET kinase domain mutations and activation of bypass signaling pathways (MET, EGFR). Furthermore, substantial variability persists across international guidelines regarding optimal prophylactic surgery timing and criteria for initiating systemic treatment. Conclusion: Future efforts must concentrate on establishing unified, dynamic risk stratification protocols, standardizing advanced imaging utilization, and implementing liquid biopsy (ctDNA) guided sequential therapy to effectively overcome acquired resistance and ensure durable long-term disease control.